ArticleEmerging infectious diseases2020
Nationwide External Quality Assessment of SARS-CoV-2 Molecular Testing, South Korea.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Update of Guidelines for Laboratory Diagnosis of COVID-19 in Korea.Annals of laboratory medicine · 2022Guideline
- Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part V – Benefits for stakeholders other than participantsClinical chemistry and laboratory medicine · 2025Review
- External Quality Assessment Program for SARS-COV-2 Molecular Detection in Pakistan.Influenza and other respiratory viruses · 2024Article
- External Quality Assessment (EQA) for SARS-CoV-2 RNA Point-of-Care Testing in Primary Healthcare Services: Analytical Performance over Seven EQA Cycles.Diagnostics (Basel, Switzerland) · 2024Article
- Optimizing heat inactivation for SARS-CoV-2 at 95 °C and its implications: A standardized approach.Heliyon · 2024Article
- High quality of SARS-CoV-2 molecular diagnostics in a diverse laboratory landscape through supported benchmark testing and External Quality Assessment.Scientific reports · 2024Article
- Current status of pathogen handling in European laboratories: focus on viral inactivation process.Frontiers in bioengineering and biotechnology · 2024Article
- Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021.Journal of virological methods · 2023Article
- Development of a national proficiency test for SARS-CoV-2 detection by PCR in Colombia.Journal of global health · 2023Article
- How South Africa Used National Cycle Threshold (Ct) Values to Continuously Monitor SARS-CoV-2 Laboratory Test Quality.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Comparison of fifteen SARS-CoV-2 nucleic acid amplification test assays used during the Canadian Laboratory Response Network's National SARS-CoV-2 Proficiency Program, May 2020 to June 2021.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- Relationship between viral load and symptoms in children infected with SARS-CoV-2.Pediatric research · 2023Article
- Ensuring diagnostic testing accuracy for patient care and public health- COVID-19 testing scale-up from an EQA provider's perspective.PLOS global public health · 2023Article
- External quality assessment for laboratories in pan-India ILI/SARI surveillance for simultaneous detection of influenza virus and SARS-CoV-2.Frontiers in public health · 2023Article
- An external quality assessment for the molecular testing of the SARS-CoV-2 virus genome in Zhejiang Province, China.Diagnostic microbiology and infectious disease · 2022Article
- External quality assessment of SARS-CoV-2 serology in European expert laboratories, April 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Tracing and testing multiple generations of contacts to COVID-19 cases: cost-benefit trade-offs.Royal Society open science · 2022Article
- Digital PCR Applications in the SARS-CoV-2/COVID-19 Era: a Roadmap for Future Outbreaks.Clinical microbiology reviews · 2022Review
- Concerns Regarding Validity of the Use of Bean Extract-Based Gargle for COVID-19 Diagnosis.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
External quality assessment (EQA) is essential for ensuring reliable test results, especially when laboratories are using assays authorized for emergency use for newly emerging pathogens. We developed an EQA panel to assess the quality of real-time reverse transcription PCR assays being used in South Korea to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the participation of 23 public health organization laboratories and 95 nongovernmental laboratories involved in SARS-CoV-2 testing, we conducted qualitative and semiquantitative performance assessments by using pooled respiratory samples containing different viral loads of SARS-CoV-2 or human coronavirus OC43. A total of 110 (93.2%) laboratories reported correct results for all qualitative tests; 29 (24.6%) laboratories had >1 outliers according to cycle threshold values. Our EQA panel identified the potential weaknesses of currently available commercial reagent kits. The methodology we used can provide practical experience for those planning to conduct evaluations for testing of SARS-CoV-2 and other emerging pathogens in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.